This video features Juan Vera, Chief Development Officer at Marker Therapeutics, discussing how Marker used G-Rex Bioreactors and the Lovo Cell Processing System to evolve and simplify manufacturing of its multiple tumor-associated antigen (MultiTAA) T cell therapy in anticipation of commercialization.
This ScaleReady-sponsored seminar originally aired at the CAR-TCR Virtual 2021 Conference (Hanson Wade) on September 1st, 2021.
Determining Optimal Seeding Density for Human T Cell Expansion in G-Rex
This scientific poster investigates the kinetics of human T cell expansion in small scale G-Rex6M bioreactors using ScaleReady reagents. Data show the affect of seeding density on fold expansion, total cell yield, and phenotypic phenotypic composition of expanded T cells, including total and memory CD4+ and CD8+ cells.